Individualized Therapy For Asthma in Toddlers
Overview
- Phase
- Phase 3
- Intervention
- daily fluticasone propionate
- Conditions
- Asthma
- Sponsor
- Milton S. Hershey Medical Center
- Enrollment
- 300
- Locations
- 13
- Primary Endpoint
- Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The INFANT study will test whether, in preschool children 12-59 months of age with persistent asthma, the following Step 2 asthma therapies will provide similar degrees of asthma control:
- Daily inhaled corticosteroid (ICS) treatment,
- Daily leukotriene receptor antagonist (LTRA) treatment, and
- As-needed ICS plus short-acting beta agonist (as-needed ICS/SABA) rescue treatment.
Detailed Description
INFANT is a double-blind, randomized clinical trial in which all participants will receive each of the three therapies for 16 weeks by means of a cross-over study design. INFANT aims to determine whether individual children respond better to one treatment than another and, if so, whether those children can be identified by phenotypic characteristics or selected biomarkers. In this regard the INFANT study is expected to address critical gaps in current asthma management guidelines. Ultimately, the findings from this study are expected to help clarify treatment modalities for this population of young preschool children who are extremely difficult to treat.
Investigators
dave mauger
Principal Investigator, AsthmaNet Data Coordinating Center
Milton S. Hershey Medical Center
Eligibility Criteria
Inclusion Criteria
- •12-59 months of age.
- •If the child is not currently taking long-term asthma controller therapy (meaning that the child has taken no inhaled corticosteroid or leukotriene receptor antagonist medication whatsoever over the past 6 months), then one of the following criteria must be met:
- •Daytime asthma symptoms more than two days per week (average over the past 4 weeks),
- •At least one nighttime awakening from asthma (over the past 4 weeks),
- •Two or more asthma exacerbations requiring systemic corticosteroids in the previous 6 months,
- •Four or more wheezing episodes in the previous 12 months.
- •If the child is currently taking long-term asthma controller therapy (meaning that the child has taken daily or intermittent/as-needed inhaled corticosteroid or leukotriene receptor antagonist over the past 6 months), then one of the following criteria must be met:
- •Taking inhaled corticosteroid or leukotriene receptor antagonist for more than 3 months (or more than 90 days) out of the previous 6 months (or 180 days),
- •Daytime asthma symptoms more than two days per week (average over the past 4 weeks),
- •More than one nighttime awakening from asthma (over the past 4 weeks),
Exclusion Criteria
- •Allergic reaction to the study medications or any component of the study drugs, including (but not limited to) urticaria, rash, angioedema, or hypotension following delivery,
- •Chronic medical disorders that could interfere with drug metabolism/excretion (for instance chronic hepatic, biliary, or renal disease),
- •Chronic medical disorders that may increase the risk of drug-related injury, including (but not limited to):
- •Osteogenesis imperfecta (increased risk of bone demineralization/fracture with corticosteroid therapy),
- •Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting disorders, or Factor deficiency (increased risk of bleeding with corticosteroid therapy),
- •G6PD deficiency (increased risk of hemolytic anemia with acetaminophen use),
- •Phenylketonuria (potential for aspartame exposure with study interventions),
- •Seizure disorder treated with anticonvulsants (risk of acetaminophen toxicity with carbamazepine), or
- •History of clotting disorders or Factor deficiency (increased risk of bleeding with corticosteroids),
- •Co-morbid disorders associated with wheezing including (but not limited to) immune deficiency disorders, cystic fibrosis, aspiration, clinically-relevant gastroesophageal reflux, tracheomalacia, congenital airway anomalies (clefts, fistulas, slings, rings), bronchiectasis, bronchopulmonary dysplasia, and/or history of premature birth before 35 weeks gestation,
Arms & Interventions
Crossover sequence 1
daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
Intervention: daily fluticasone propionate
Crossover sequence 1
daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
Intervention: Montelukast
Crossover sequence 1
daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
Intervention: as-needed fluticasone propionate
Crossover sequence 2
daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
Intervention: daily fluticasone propionate
Crossover sequence 2
daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
Intervention: Montelukast
Crossover sequence 2
daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
Intervention: as-needed fluticasone propionate
Crossover sequence 3
daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
Intervention: daily fluticasone propionate
Crossover sequence 3
daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
Intervention: Montelukast
Crossover sequence 3
daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
Intervention: as-needed fluticasone propionate
Crossover sequence 4
daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
Intervention: daily fluticasone propionate
Crossover sequence 4
daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
Intervention: Montelukast
Crossover sequence 4
daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
Intervention: as-needed fluticasone propionate
Crossover sequence 5
as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
Intervention: daily fluticasone propionate
Crossover sequence 5
as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
Intervention: Montelukast
Crossover sequence 5
as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
Intervention: as-needed fluticasone propionate
Crossover sequence 6
as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
Intervention: daily fluticasone propionate
Crossover sequence 6
as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
Intervention: Montelukast
Crossover sequence 6
as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
Intervention: as-needed fluticasone propionate
Outcomes
Primary Outcomes
Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.
Time Frame: The last 14 weeks of each 16-week treatment period
The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period.